Gila Therapeutics is a Boston-based clinical stage biotech company exploiting a novel, highly-targeted neural signaling system for the treatment of obesity, type 2 diabetes and associated metabolic disorders. Our innovative Topical Lingual Neural Signaling platform facilitates the direct activation of specific brain regions responsible for metabolic regulation through the delivery of natural peptide hormones without expectation of side effects. Our scientific advisory team is renowned globally for their unrivaled experience and pioneering contributions to the fields of endocrinology, neuroscience, and metabolic nephrology. Reach out to learn more about us.
Looking for a particular Gila Therapeutics Inc employee's phone or email?
The Gila Therapeutics Inc annual revenue was $608000 in 2026.
Thomas Vasicek is the Co-Founder and CSO of Gila Therapeutics Inc.
1 people are employed at Gila Therapeutics Inc.
Gila Therapeutics Inc is based in Boston, Massachusetts.
The NAICS codes for Gila Therapeutics Inc are [5417, 54, 541, 54171, 541714].
The SIC codes for Gila Therapeutics Inc are [873, 87].